CareDx organ-transplant patents ineligible, affirms Fed. Circuit [Reuters]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Reuters
Court says patents use conventional techniques to test patients' blood for potential organ rejection (Reuters) - Natera Inc and Eurofins Viracor Inc defeated rival CareDx Inc's claims on Monday that their tests for determining a transplant patient's risk of organ rejection infringe its patents. CareDx's patents cover conventional, patent-ineligible methods for detecting DNA levels in the blood, the U.S. Court of Appeals for the Federal Circuit said , affirming a Delaware court decision. CareDx attorney Edward Reines of Weil, Gotshal & Manges said the Federal Circuit's Monday decision is "the most restrictive patent-eligibility decision yet, which will further suffocate innovation in the life-saving arts." Patent eligibility is a polarizing issue for attorneys and judges, and critics have said conflicting court precedent has produced unpredictable decisions and undermined the U.S. patent process. The U.S. Supreme Court turned away a request to hear a closely watched case on th
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $90.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
- Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]Yahoo! Finance
- Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation [Yahoo! Finance]Yahoo! Finance
- Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney TransplantationBusiness Wire
- FBT: An Equal Weight Way To Play Biotech [Seeking Alpha]Seeking Alpha
NTRA
Earnings
- 2/28/24 - Beat
NTRA
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/16/24 - Form 144
- NTRA's page on the SEC website